
We Claim:

1. A method for preparing a crystalline compound of Formula (II)



(II)

comprising (i) preparing a solution of a compound of Formula (II) in an organic solvent; (ii) bringing the solution to supersaturation to cause formation of crystals; and (iii) isolating the crystals.

2. A method of claim 1, wherein the organic solvent is selected from acetonitrile, acetone, diethyl ether, diisopropyl ether, ethyl acetate, heptanes, isopropyl acetate, methanol, methyl tert-butyl ether, tetrahydrofuran, toluene, or any combination thereof.

3. A method of claim 2, wherein the organic solvent is selected from toluene, methyl tert-butyl ether, heptanes, or a combination thereof.

4. A method of claim 1, wherein bringing the solution to supersaturation comprises addition of an anti-solvent, allowing the solution to cool, reducing the volume of the solution, or any combination thereof.

5. A method of claim 4, wherein bringing the solution to supersaturation comprises cooling the solution to ambient temperature and reducing the volume of the solution.

6. A method of claim 1, further comprising washing the crystals.

7. A method of claim 6, wherein the washing comprises washing with a liquid selected from anti-solvent, acetonitrile, acetone, diethyl ether, diisopropyl ether, ethanol, ethyl acetate, heptanes, isopropyl acetate, methanol, methyl tert-butyl ether, tetrahydrofuran, toluene, or any combination thereof, or a combination thereof.

8. A method of claim 8, wherein washing comprises washing with a combination toluene and methyl tert-butyl ether.

9. A method of claim 7 wherein washing comprises washing with toluene.


10. A method of claim 1, wherein isolating the crystals comprises filtering the crystals.

11. A method of claim 1, further comprising drying the crystals under reduced pressure.

12. A method of claim 1, wherein the crystalline compound of Formula (II) is a solvate.

13. A method of claim 12, wherein the crystalline compound of Formula (II) is a toluene solvate.

14. A crystalline compound having a structure of Formula (II)



(II).

15. A crystalline compound of claim 14, having a DSC thermogram substantially as shown in Figure 1.

16. A crystalline compound of claim 14, having an XRPD pattern substantially as shown in Figure 2.

17. A crystalline compound of claim 14 having 2θ values 3.62±0.20; 6.52±0.20; 7.20±0.20; 8.66±0.20; 10.04±0.20; 10.82±0.20; 12.98±0.20; 14.42±0.20; 16.46±0.20; 17.32±0.20; 17.98±0.20; 18.02±0.20; 18.88±0.20; 19.06±0.20; 19.56±0.20; 19.88±0.20; 20.40±0.20; 21.36±0.20; 22.16±0.20; 23.20±0.20; 25.40±0.20; 28.82±0.20.

18. A crystalline compound of claim 14, which is a solvate.

19. A crystalline compound of claim 18, which is a toluene solvate.

20. Use of a crystalline compound of claim 14 in the manufacture of a medicament for treating a disease or condition selected from an immune -related disease, cancer, inflammation, infection, proliferative disease, or neurodegenerative disease.

21. The use of claim 20, wherein the disease or condition is an immune-related disease.

22. The use of claim 21, wherein the immune-related disease is selected from autoimmune disease, Crohn's disease, diabetes, lupus, multiple sclerosis, myositis, psoriasis, rheumatoid arthritis and ulcerative colitis.

23. The use of claim 20, wherein the disease or condition is cancer.

24. The use of claim 23, wherein the cancer is selected from leukemia, lymphoma and multiple myeloma.

25. The use of claim 20, wherein the disease or condition is inflammation.


26. The use of claim 20, wherein the disease or condition is an infection.

27. The use of claim 20, wherein the disease or condition is a proliferative disease.

28. The use of claim 20, wherein the disease or condition is a neurodegenerative disease.

We Claim:

1. A method for preparing a crystalline compound of Formula (II)



(II)

wherein the crystalline compound has 2θ values 3.62±0.20; 6.52±0.20; 7.20±0.20; 8.66±0.20; 10.04±0.20; 10.82±0.20; 12.98±0.20; 14.42±0.20; 16.46±0.20; 17.32±0.20; 17.98±0.20; 18.02±0.20; 18.88±0.20; 19.06±0.20; 19.56±0.20; 19.88±0.20; 20.40±0.20; 21.36±0.20; 22.16±0.20; 23.20±0.20; 25.40±0.20; and 28.82±0.20,

comprising (i) preparing a solution of a compound of Formula (II) in an organic solvent;

(ii) bringing the solution to supersaturation to cause formation of crystals; and

(iii) isolating the crystals.

2. A method of claim 1, wherein the organic solvent is selected from acetonitrile, acetone, diethyl ether, diisopropyl ether, ethyl acetate, heptanes, isopropyl acetate, methanol, methyl tert-butyl ether, tetrahydrofuran, toluene, or any combination thereof.

3. A method of claim 2, wherein the organic solvent is selected from toluene, methyl tert-butyl ether, heptanes, or a combination thereof.

4. A method of claim 1, wherein bringing the solution to supersaturation comprises addition of an anti-solvent, allowing the solution to cool, reducing the volume of the solution, or any combination thereof.

5. A method of claim 4, wherein bringing the solution to supersaturation comprises cooling the solution to ambient temperature and reducing the volume of the solution.

6. A method of claim 1, further comprising washing the crystals.

7. A method of claim 6, wherein the washing comprises washing with a liquid selected from anti-solvent, acetonitrile, acetone, diethyl ether, diisopropyl ether, ethanol, ethyl acetate, heptanes, isopropyl acetate, methanol, methyl tert-butyl ether, tetrahydrofuran, toluene, or any combination thereof, or a combination thereof.

8. A method of claim 7, wherein washing comprises washing with a combination of toluene and methyl tert-butyl ether.

9. A method of claim 7, wherein washing comprises washing with toluene.


10. A method of claim 1, wherein isolating the crystals comprises filtering the crystals.

11. A method of claim 1, further comprising drying the crystals under reduced pressure.

12. A method of claim 1, wherein the crystalline compound of Formula (II) is a solvate.

13. A method of claim 12, wherein the crystalline compound of Formula (II) is a toluene solvate.

14. A crystalline compound having a structure of Formula (II)



(II)

wherein the crystalline compound has 2θ values 3.62±0.20; 6.52±0.20; 7.20±0.20; 8.66±0.20; 10.04±0.20; 10.82±0.20; 12.98±0.20; 14.42±0.20; 16.46±0.20; 17.32±0.20; 17.98±0.20; 18.02±0.20; 18.88±0.20; 19.06±0.20; 19.56±0.20; 19.88±0.20; 20.40±0.20; 21.36±0.20; 22.16±0.20; 23.20±0.20; 25.40±0.20; and 28.82±0.20.

15. A crystalline compound of claim 14, having a DSC thermogram substantially as shown in Figure 1.

16. A crystalline compound of claim 14, having an XRPD pattern substantially as shown in Figure 2.

17. A crystalline compound of claim 14, which is a solvate.

18. A crystalline compound of claim 17, which is a toluene solvate.

19. Use of a crystalline compound of claim 14 in the manufacture of a medicament for treating a disease or condition selected from an immune-related disease, cancer, inflammation, infection, proliferative disease, or neurodegenerative disease.

20. The use of claim 19, wherein the disease or condition is an immune-related disease.

21. The use of claim 20, wherein the immune-related disease is selected from autoimmune disease, Crohn's disease, diabetes, lupus, multiple sclerosis, myositis, psoriasis, rheumatoid arthritis and ulcerative colitis.

22. The use of claim 19, wherein the disease or condition is cancer.

23. The use of claim 22, wherein the cancer is selected from leukemia, lymphoma and multiple myeloma.

24. The use of claim 19, wherein the disease or condition is inflammation.

25. The use of claim 19, wherein the disease or condition is an infection.

26. The use of claim 19, wherein the disease or condition is a proliferative disease.

27. The use of claim 19, wherein the disease or condition is a neurodegenerative disease.